PA8776801A1 - Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson. - Google Patents

Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson.

Info

Publication number
PA8776801A1
PA8776801A1 PA20088776801A PA8776801A PA8776801A1 PA 8776801 A1 PA8776801 A1 PA 8776801A1 PA 20088776801 A PA20088776801 A PA 20088776801A PA 8776801 A PA8776801 A PA 8776801A PA 8776801 A1 PA8776801 A1 PA 8776801A1
Authority
PA
Panama
Prior art keywords
piridin
metoxi
dicloro
oxido
carboxamide
Prior art date
Application number
PA20088776801A
Other languages
English (en)
Spanish (es)
Inventor
Delay-Goyet Philippe
Ravinet-Trillou Christine
Delgorge Claire
Poughon Gilles
Menet Christine
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8776801A1 publication Critical patent/PA8776801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
PA20088776801A 2007-04-19 2008-04-15 Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson. PA8776801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
PA8776801A1 true PA8776801A1 (es) 2008-11-19

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088776801A PA8776801A1 (es) 2007-04-19 2008-04-15 Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson.

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR20150004885A (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955808A (zh) * 2012-11-28 2015-09-30 赛诺菲 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的晶型的制备方法以及晶型
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025080415A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
ATE218549T1 (de) * 1993-07-28 2002-06-15 Aventis Pharma Ltd Verbindungen als pde iv und tnf inhibitoren
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
EP1370211A4 (en) * 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
AU2003281219A1 (en) * 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
AU2004220456B2 (en) * 2003-03-12 2010-10-14 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
CA2684174C (fr) 2014-02-25
FR2915100A1 (fr) 2008-10-24
PT2146714E (pt) 2011-09-02
JO2678B1 (en) 2013-03-03
CA2684174A1 (fr) 2008-12-04
ZA200907251B (en) 2011-04-28
ATE513548T1 (de) 2011-07-15
EP2146714B1 (fr) 2011-06-22
CN101663035B (zh) 2012-06-20
US20100130554A1 (en) 2010-05-27
HK1141725A1 (en) 2010-11-19
HRP20110666T1 (hr) 2011-10-31
KR20150004885A (ko) 2015-01-13
KR20090130059A (ko) 2009-12-17
UY31035A1 (es) 2008-11-28
BRPI0810444A2 (pt) 2016-05-31
CN101663035A (zh) 2010-03-03
DK2146714T3 (da) 2011-10-10
SI2146714T1 (sl) 2011-10-28
ES2367408T3 (es) 2011-11-03
EA200970970A1 (ru) 2010-02-26
JP5386478B2 (ja) 2014-01-15
CL2008001136A1 (es) 2009-01-16
FR2915100B1 (fr) 2009-06-05
MY148092A (en) 2013-02-28
CY1111840T1 (el) 2015-10-07
TWI439269B (zh) 2014-06-01
AR066108A1 (es) 2009-07-22
AU2008257322A1 (en) 2008-12-04
KR101503942B1 (ko) 2015-03-18
TW200911247A (en) 2009-03-16
IL201448A (en) 2014-08-31
WO2008145841A1 (fr) 2008-12-04
MX2009011284A (es) 2009-11-02
RS51869B (sr) 2012-02-29
EA019194B1 (ru) 2014-01-30
ME00935B (me) 2012-06-20
AU2008257322B2 (en) 2013-06-13
MA31367B1 (fr) 2010-05-03
PL2146714T3 (pl) 2011-10-31
IL201448A0 (en) 2010-05-31
EP2146714A1 (fr) 2010-01-27
NZ580482A (en) 2011-10-28
JP2010524906A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
ECSP088504A (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CR7261A (es) Derivados de diarilcicloalquilo, procedimiento para su preparacion y su utilizacion como agentes activadores del ppar
CL2011002955A1 (es) Compuestos derivados de 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octanonitrilo o heptanonitrilo o sus sales, como inhibidores de jak; procedimiento de preparacion; composicion farmaceutica que los comprende; utiles para el tratamiento de trastornos autoinmunes, cancer, entre otras enfermedades.
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
CR11013A (es) Forma de dosificacion novedosa
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
BRPI0807804A2 (pt) " arilciclopentenos substituídos como agentes terapêuticos ".
CR11734A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
PA8776801A1 (es) Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson.
PA8776601A1 (es) Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1- oxido-piridin-4-il)-5(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la medula espinal
GT200500328A (es) Sal l-tartrato de n-1-adamantil-2-{3-[(2r)-2-({(2r)-2-hidroxi-2[4-hidroxi-3-(hidroximetil)fenil]etil}amino)propil]fenil}acetamida.
GT200900037A (es) Compuestos organicos